INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Retifanlimab
Related studies linked through entity extraction aliases.
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
- Status
- RECRUITING
- Phase
- PHASE2
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of INCA 0186 in Subjects With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Status
- TERMINATED
- Phase
- PHASE2
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE2
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
- Status
- COMPLETED
- Phase
- PHASE2
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3